drugset / Trial / NCT01196169

Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty

NCT01196169

RandomizedParallel-groupOpen-labelPrevention

Summary

This study will evaluate the safety and effectiveness of daptomycin, an antibiotic compared to another one which is vancomycin when given around the time of joint replacement surgery. Vancomycin is recommended for perioperative prophylaxis in methicillin resistant Staphylococcus aureus (MRSA) colonized patients undergoing primary total joint arthroplasty. Daptomycin has not been recommended for this indication but it is FDA approved for treatment of MRSA blood stream and skin and soft tissue infections. Data collected during this study may support the use of daptomycin for this indication and may also be used for other research purposes that have not yet been specified.

Timeline

Start
2010-10
Primary completion
2014-03
Completion
2014-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Daptomycin Other / unclassified 6 mg/kg Intravenous
Comparator Vancomycin Other / unclassified 15 mg/kg Intravenous